Overview

A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

Status:
NOT_YET_RECRUITING

Trial end date:
2026-01-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.

Phase:

PHASE1

Details

Lead Sponsor:

BeiGene

Treatments:

zanubrutinib